Show simple item record

dc.contributor.authorColeman, R
dc.contributor.authorOza, A
dc.contributor.authorLorusso, D
dc.contributor.authorAghajanian, C
dc.contributor.authorOaknin, A
dc.contributor.authorDean, A
dc.contributor.authorColombo, N
dc.contributor.authorWeberpals, J
dc.contributor.authorClamp, Andrew R
dc.contributor.authorScambia, G
dc.contributor.authorLeary, A
dc.contributor.authorHolloway, R
dc.contributor.authorO’Malley, D
dc.contributor.authorCameron, T
dc.contributor.authorMaloney, L
dc.contributor.authorGoble, S
dc.contributor.authorLin, K
dc.contributor.authorSun, J
dc.contributor.authorGiordano, H
dc.contributor.authorLedermann, J
dc.date.accessioned2018-10-15T16:46:05Z
dc.date.available2018-10-15T16:46:05Z
dc.date.issued2018-08-01
dc.identifier.citationARIEL3: a phase 3, randomized, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian cancer (OC). 2018, 24(15_Suppl): 30-31 Clin Cancer Resen
dc.identifier.doi10.1158/1557-3265.OVCA17-PR06
dc.identifier.urihttp://hdl.handle.net/10541/621270
dc.language.isoenen
dc.relation.urlhttp://clincancerres.aacrjournals.org/lookup/doi/10.1158/1557-3265.OVCA17-PR06en
dc.titleARIEL3: a phase 3, randomized, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian cancer (OC).en
dc.typeMeetings and Proceedingsen
dc.contributor.departmentThe University of Texas MD Anderson Cancer Center, Houstonen
dc.identifier.journalClinical Cancer Researchen


This item appears in the following Collection(s)

Show simple item record